| Project/Area Number |
18590704
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Nippon Medical School |
|---|
Principal Investigator |
SAKAMOTO Choitsu Nippon Medical School, School of Medicine, Professor (30196092)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,890,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥390,000)
Fiscal Year 2007: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2006: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | COX-2 / H.Dvlori / intestinal metanlasia / gastric cancer / selectice COX-2 antagonist / Cdx2 / 選択的COX-2阻害薬 / セレコキシブ / スナネズミ / h.pylori |
|---|
| Research Abstract |
The aim of this study was to see whether administration of celecoxib, a selective COX-2 inhibitor, prior to the appearance of intestinal metaplasia could prevent the development of gastric cancer in Helicobacter pylorrinfected Mongolian gerbils. The incidence of gastric adenocarcinoma was : controls, 0% (0/10) ; H. pylori group, 65% (13/20), and H. pylori plus celecoxib group, 23% (5/22 ; p < 0.05). Continuous celecoxib administration significantly reduced COX activity and COX-2 protein expression, Cdx2 and MUC2 protein immunoreactivity, and the extent of Alcian blue periodic acid-Schiff-positive intestinal metaplasia in H. pylori-infected gerbils. Celecoxib also induced apoptosis in these gerbils. Significant inhibition of Cdx2 expression in celecoxib group was also shown by Western blot analysis. Prior to the first appearance of intestinal metaplasia, timely administration of celecoxib prevents gastric cancer occurrence by disrupting the progression of intestinal metaplasia into gastric carcinoma through its inhibition of Cdx2 expression in H. pylori-infected Mongolian gerbils.
|
